Rivus Pharmaceuticals

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
Mitochondrial uncouplingSmall molecule
Heart FailureMASH / NASH

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
February 2027 (1)
HU6Phase 2MASH - Metabolic Dysfunction-Associated Steatohepatitis
Est. primary completion 2027-02 · NCT07491458 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

24 June 2025Topline resultHU6HU6 Phase 2 M-ACCEL in MASH met its primary liver-fat endpoint
Rivus Pharmaceuticals · Source ↗

Financial reports

No financial reports recorded.